表紙:創薬の世界市場予測(2022年~2030年)
市場調査レポート
商品コード
1069202

創薬の世界市場予測(2022年~2030年)

Global Drug Discovery Market Forecast 2022-2030

出版日: | 発行: Inkwood Research | ページ情報: 英文 235 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
創薬の世界市場予測(2022年~2030年)
出版日: 2022年04月11日
発行: Inkwood Research
ページ情報: 英文 235 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の創薬の市場規模は、予測期間である2022年から2030年の間に6.58%のCAGRで成長すると予測されています。同市場の成長を推進する主な要因には、各疾患治療のための研究開発の増加や、技術の進歩が挙げられます。

地域的には、欧州と北米の国々が数十年にわたり創薬でリードしており、これは主に啓発プログラム、政府およびCROの取り組み、製薬企業などに起因しています。ただし、プロジェクトの実現可能性と成功率、高度に規制された市場、時間のかかるプロセスなどが市場成長の妨げとなっています。

当レポートでは、世界の創薬市場について調査し、市場規模や予測、市場力学、セグメント・地域別の市場分析、市場シェア、競合情勢や戦略、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査範囲と調査手法

  • 調査目的
  • 調査範囲
  • 調査手法
  • 前提条件と制限

第2章 エグゼクティブサマリー

  • 市場規模・推計
  • 市場概要

第3章 市場力学

  • 主な促進要因
    • 各疾患に取り組む研究開発の成長
    • 技術の進歩
  • 主な抑制要因
    • 膨大な時間のかかるプロセス
    • 高度に規制された市場
    • プロジェクトの実現可能性と成功率

第4章 主要な分析

  • COVID-19が市場に与える影響
  • 主な市場の動向
  • ポーターのファイブフォース分析
  • 市場機会マトリックス
  • 創薬および開発プロセス
  • 規制の枠組み

第5章 薬剤タイプ別の市場

  • 小分子薬
  • 生物学的薬剤

第6章 サービス別の市場

  • 化学サービス
  • 薬物代謝・薬物動態サービス
  • 生物学的サービス
  • その他

第7章 エンドユーザー別の市場

  • 製薬企業
  • 医薬品開発業務受託機関
  • 研究機関
  • その他

第8章 テクノロジー別の市場

  • ハイスループットスクリーニング
  • 分光法
  • コンビナトリアルケミストリー
  • バイオチップ
  • ゲノム薬理学および薬理遺伝学
  • バイオインフォマティクス
  • メタボロミクス
  • ナノテクノロジー
  • その他

第9章 地域分析

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第10章 競合情勢

  • 主な戦略的開発
    • 合併と買収
    • 製品の発売と開発
    • パートナーシップと契約
    • 事業の拡大と売却
  • 企業プロファイル
    • AGILENT TECHNOLOGIES INC
    • ASTRAZENECA PLC
    • BAYER AG
    • CHARLES RIVER LABORATORIES INTERNATIONAL INC
    • ELI LILLY AND COMPANY
    • EVOTEC SE
    • GLAXOSMITHKLINE PLC
    • ICON PLC
    • IQVIA HOLDINGS INC
    • JOHNSON & JOHNSON
    • MERCK & CO INC
    • NOVARTIS AG
    • PFIZER INC
    • ROCHE AG
図表

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - GLOBAL DRUG DISCOVERY
  • TABLE 2: REGULATORY FRAMEWORK
  • TABLE 3: GLOBAL DRUG DISCOVERY MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 4: GLOBAL DRUG DISCOVERY MARKET, BY DRUG TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 5: GLOBAL SMALL MOLECULE DRUG MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 6: GLOBAL SMALL MOLECULE DRUG MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 7: GLOBAL BIOLOGIC DRUG MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 8: GLOBAL BIOLOGIC DRUG MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 9: GLOBAL DRUG DISCOVERY MARKET, BY SERVICE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 10: GLOBAL DRUG DISCOVERY MARKET, BY SERVICE, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 11: GLOBAL CHEMICAL SERVICES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 12: GLOBAL CHEMICAL SERVICES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 13: GLOBAL DRUG METABOLISM AND PHARMACOKINETICS SERVICES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 14: GLOBAL DRUG METABOLISM AND PHARMACOKINETICS SERVICES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 15: GLOBAL BIOLOGICAL SERVICES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 16: GLOBAL BIOLOGICAL SERVICES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 17: GLOBAL OTHER PHARMACEUTICAL SERVICES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 18: GLOBAL OTHER PHARMACEUTICAL SERVICES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 19: GLOBAL DRUG DISCOVERY MARKET, BY END-USERS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 20: GLOBAL DRUG DISCOVERY MARKET, BY END-USERS, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 21: GLOBAL PHARMACEUTICAL COMPANIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 22: GLOBAL PHARMACEUTICAL COMPANIES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 23: GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 24: GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 25: GLOBAL RESEARCH INSTITUTES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 26: GLOBAL RESEARCH INSTITUTES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 27: GLOBAL OTHER END-USERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 28: GLOBAL OTHER END-USERS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 29: GLOBAL DRUG DISCOVERY MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 30: GLOBAL DRUG DISCOVERY MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 31: GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 32: GLOBAL HIGH THROUGHPUT SCREENING MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 33: GLOBAL SPECTROSCOPY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 34: GLOBAL SPECTROSCOPY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 35: GLOBAL COMBINATORIAL CHEMISTRY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 36: GLOBAL COMBINATORIAL CHEMISTRY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 37: GLOBAL BIOCHIPS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 38: GLOBAL BIOCHIPS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 39: GLOBAL PHARMACOGENOMICS AND PHARMACOGENETICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 40: GLOBAL PHARMACOGENOMICS AND PHARMACOGENETICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 41: GLOBAL BIOINFORMATICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 42: GLOBAL BIOINFORMATICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 43: GLOBAL METABOLOMICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 44: GLOBAL METABOLOMICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 45: GLOBAL NANOTECHNOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 46: GLOBAL NANOTECHNOLOGY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 47: GLOBAL OTHER TECHNOLOGIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 48: GLOBAL OTHER TECHNOLOGIES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 49: GLOBAL DRUG DISCOVERY MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 50: GLOBAL DRUG DISCOVERY MARKET, BY GEOGRAPHY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 51: NORTH AMERICA DRUG DISCOVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 52: NORTH AMERICA DRUG DISCOVERY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 53: LEADING PLAYERS OPERATING IN NORTH AMERICA DRUG DISCOVERY MARKET
  • TABLE 54: EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 55: EUROPE DRUG DISCOVERY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 56: LEADING PLAYERS OPERATING IN EUROPE DRUG DISCOVERY MARKET
  • TABLE 57: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 58: ASIA-PACIFIC DRUG DISCOVERY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 59: LEADING PLAYERS OPERATING IN ASIA-PACIFIC DRUG DISCOVERY MARKET
  • TABLE 60: REST OF WORLD DRUG DISCOVERY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
  • TABLE 61: REST OF WORLD DRUG DISCOVERY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)
  • TABLE 62: LEADING PLAYERS OPERATING IN REST OF WORLD DRUG DISCOVERY MARKET
  • TABLE 63: LIST OF MERGERS & ACQUISITIONS
  • TABLE 64: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 65: LIST OF PARTNERSHIPS & AGREEMENTS
  • TABLE 66: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

  • FIGURE 1: KEY MARKET TRENDS
  • FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 3: OPPORTUNITY MATRIX
  • FIGURE 4: DRUG DISCOVERY AND DEVELOPMENT PROCESS
  • FIGURE 5: GLOBAL DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2021
  • FIGURE 6: GLOBAL DRUG DISCOVERY MARKET, BY SMALL MOLECULE DRUG, 2022-2030 (IN $ MILLION)
  • FIGURE 7: GLOBAL DRUG DISCOVERY MARKET, BY BIOLOGIC DRUG, 2022-2030 (IN $ MILLION)
  • FIGURE 8: GLOBAL DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY SERVICE, IN 2021
  • FIGURE 9: GLOBAL DRUG DISCOVERY MARKET, BY CHEMICAL SERVICES, 2022-2030 (IN $ MILLION)
  • FIGURE 10: GLOBAL DRUG DISCOVERY MARKET, BY DRUG METABOLISM AND PHARMACOKINETICS SERVICES, 2022-2030 (IN $ MILLION)
  • FIGURE 11: GLOBAL DRUG DISCOVERY MARKET, BY BIOLOGICAL SERVICES, 2022-2030 (IN $ MILLION)
  • FIGURE 12: GLOBAL DRUG DISCOVERY MARKET, BY OTHER PHARMACEUTICAL SERVICES, 2022-2030 (IN $ MILLION)
  • FIGURE 13: GLOBAL DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY END-USERS, IN 2021
  • FIGURE 14: GLOBAL DRUG DISCOVERY MARKET, BY PHARMACEUTICAL COMPANIES, 2022-2030 (IN $ MILLION)
  • FIGURE 15: GLOBAL DRUG DISCOVERY MARKET, BY CONTRACT RESEARCH ORGANIZATIONS, 2022-2030 (IN $ MILLION)
  • FIGURE 16: GLOBAL DRUG DISCOVERY MARKET, BY RESEARCH INSTITUTES, 2022-2030 (IN $ MILLION)
  • FIGURE 17: GLOBAL DRUG DISCOVERY MARKET, BY OTHER END-USERS, 2022-2030 (IN $ MILLION)
  • FIGURE 18: GLOBAL DRUG DISCOVERY MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021
  • FIGURE 19: GLOBAL DRUG DISCOVERY MARKET, BY HIGH THROUGHPUT SCREENING, 2022-2030 (IN $ MILLION)
  • FIGURE 20: GLOBAL DRUG DISCOVERY MARKET, BY SPECTROSCOPY, 2022-2030 (IN $ MILLION)
  • FIGURE 21: GLOBAL DRUG DISCOVERY MARKET, BY COMBINATORIAL CHEMISTRY, 2022-2030 (IN $ MILLION)
  • FIGURE 22: GLOBAL DRUG DISCOVERY MARKET, BY BIOCHIPS, 2022-2030 (IN $ MILLION)
  • FIGURE 23: GLOBAL DRUG DISCOVERY MARKET, BY PHARMACOGENOMICS AND PHARMACOGENETICS, 2022-2030 (IN $ MILLION)
  • FIGURE 24: GLOBAL DRUG DISCOVERY MARKET, BY BIOINFORMATICS, 2022-2030 (IN $ MILLION)
  • FIGURE 25: GLOBAL DRUG DISCOVERY MARKET, BY METABOLOMICS, 2022-2030 (IN $ MILLION)
  • FIGURE 26: GLOBAL DRUG DISCOVERY MARKET, BY NANOTECHNOLOGY, 2022-2030 (IN $ MILLION)
  • FIGURE 27: GLOBAL DRUG DISCOVERY MARKET, BY OTHER TECHNOLOGIES, 2022-2030 (IN $ MILLION)
  • FIGURE 28: NORTH AMERICA DRUG DISCOVERY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 29: UNITED STATES DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 30: CANADA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 31: EUROPE DRUG DISCOVERY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 32: UNITED KINGDOM DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 33: GERMANY DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 34: FRANCE DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 35: ITALY DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 36: RUSSIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 37: SPAIN DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 38: SCANDINAVIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 39: REST OF EUROPE DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 40: ASIA-PACIFIC DRUG DISCOVERY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 41: CHINA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 42: JAPAN DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 43: INDIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 44: SOUTH KOREA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 45: INDONESIA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 46: SINGAPORE DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 47: TAIWAN DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 48: AUSTRALIA & NEW ZEALAND DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 49: REST OF ASIA-PACIFIC DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 50: REST OF WORLD DRUG DISCOVERY MARKET, REGIONAL OUTLOOK, 2021 & 2030 (IN %)
  • FIGURE 51: LATIN AMERICA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
  • FIGURE 52: MIDDLE EAST & AFRICA DRUG DISCOVERY MARKET, 2022-2030 (IN $ MILLION)
目次
Product Code: 13150

KEY FINDINGS

The global drug discovery market is projected to register a CAGR of 6.58% during the forecast period, 2022-2030. The increasing R&D efforts for multiple diseases cure and the technological advancements are the primary factors propelling the market growth.

MARKET INSIGHTS

Drug discovery entails identifying the potential new medicines in a vast range of scientific disciplines like pharmacology, chemistry, and biology. The drug discovery process landscape has witnessed radical changes with innovative methods and technologies for drug development. This has enabled research organizations and pharmaceutical companies to find solutions and cures for several diseases and health conditions. In addition, companies are introducing nanotechnology, biochips, automated processes, cloud computing, and artificial intelligence.

At the same time, the process of new drug discovery and development needs almost 10-15 years, encompassing preliminary research to introducing drugs to the market. Also, there are risks associated with any development phase that must be considered.

Geographically, the European and North American countries have excelled for decades in drug discovery, majorly attributed to awareness programs, government & CRO initiatives, pharmaceutical companies, etc. The market growth restraining factors include project feasibility & success rate, highly regulated market, and time-consuming process.

REGIONAL INSIGHTS

The global drug discovery market growth analysis includes the geographical assessment of North America, Europe, Asia-Pacific, and Rest of World. North America is the leading region with regard to the highest revenue share, mostly attributed to advancements in various technologies.

COMPETITIVE INSIGHTS

The intense competitive rivalry is due to the collaborations, partnerships, and fund projects among new market players. Some of the leading companies in the market include Roche AG, Eli Lilly and Company, Johnson & Johnson, Novartis AG, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. KEY DRIVERS
    • 3.1.1. GROWING R&D FOR TACKLING SEVERAL DISEASES
    • 3.1.2. TECHNOLOGICAL ADVANCEMENTS
  • 3.2. KEY RESTRAINTS
    • 3.2.1. EXTENSIVE TIME-CONSUMING PROCESS
    • 3.2.2. HIGHLY REGULATED MARKET
    • 3.2.3. PROJECT FEASIBILITY AND SUCCESS RATE

4. KEY ANALYTICS

  • 4.1. IMPACT OF COVID-19 ON GLOBAL DRUG DISCOVERY MARKET
  • 4.2. KEY MARKET TRENDS
  • 4.3. PORTER'S FIVE FORCES ANALYSIS
    • 4.3.1. BUYERS POWER
    • 4.3.2. SUPPLIERS POWER
    • 4.3.3. SUBSTITUTION
    • 4.3.4. NEW ENTRANTS
    • 4.3.5. INDUSTRY RIVALRY
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. DRUG DISCOVERY AND DEVELOPMENT PROCESS
    • 4.5.1. DRUG DISCOVERY AND DEVELOPMENT
    • 4.5.2. PRECLINICAL RESEARCH
    • 4.5.3. CLINICAL RESEARCH
    • 4.5.4. REGULATORY AUTHORITY REVIEW
    • 4.5.5. POST MARKET SAFETY MONITORING
  • 4.6. REGULATORY FRAMEWORK

5. MARKET BY DRUG TYPE

  • 5.1. SMALL MOLECULE DRUG
  • 5.2. BIOLOGIC DRUG

6. MARKET BY SERVICE

  • 6.1. CHEMICAL SERVICES
  • 6.2. DRUG METABOLISM AND PHARMACOKINETICS SERVICES
  • 6.3. BIOLOGICAL SERVICES
  • 6.4. OTHER PHARMACEUTICAL SERVICES

7. MARKET BY END-USERS

  • 7.1. PHARMACEUTICAL COMPANIES
  • 7.2. CONTRACT RESEARCH ORGANIZATIONS
  • 7.3. RESEARCH INSTITUTES
  • 7.4. OTHER END-USERS

8. MARKET BY TECHNOLOGY

  • 8.1. HIGH THROUGHPUT SCREENING
  • 8.2. SPECTROSCOPY
  • 8.3. COMBINATORIAL CHEMISTRY
  • 8.4. BIOCHIPS
  • 8.5. PHARMACOGENOMICS AND PHARMACOGENETICS
  • 8.6. BIOINFORMATICS
  • 8.7. METABOLOMICS
  • 8.8. NANOTECHNOLOGY
  • 8.9. OTHER TECHNOLOGIES

9. GEOGRAPHICAL ANALYSIS

  • 9.1. NORTH AMERICA
    • 9.1.1. MARKET SIZE & ESTIMATES
    • 9.1.2. KEY GROWTH ENABLERS
    • 9.1.3. KEY CHALLENGES
    • 9.1.4. KEY PLAYERS
    • 9.1.5. COUNTRY ANALYSIS
      • 9.1.5.1. UNITED STATES
      • 9.1.5.2. CANADA
  • 9.2. EUROPE
    • 9.2.1. MARKET SIZE & ESTIMATES
    • 9.2.2. KEY GROWTH ENABLERS
    • 9.2.3. KEY CHALLENGES
    • 9.2.4. KEY PLAYERS
    • 9.2.5. COUNTRY ANALYSIS
      • 9.2.5.1. UNITED KINGDOM
      • 9.2.5.2. GERMANY
      • 9.2.5.3. FRANCE
      • 9.2.5.4. ITALY
      • 9.2.5.5. RUSSIA
      • 9.2.5.6. SPAIN
      • 9.2.5.7. SCANDINAVIA
      • 9.2.5.8. REST OF EUROPE
  • 9.3. ASIA-PACIFIC
    • 9.3.1. MARKET SIZE & ESTIMATES
    • 9.3.2. KEY GROWTH ENABLERS
    • 9.3.3. KEY CHALLENGES
    • 9.3.4. KEY PLAYERS
    • 9.3.5. COUNTRY ANALYSIS
      • 9.3.5.1. CHINA
      • 9.3.5.2. JAPAN
      • 9.3.5.3. INDIA
      • 9.3.5.4. SOUTH KOREA
      • 9.3.5.5. INDONESIA
      • 9.3.5.6. SINGAPORE
      • 9.3.5.7. TAIWAN
      • 9.3.5.8. AUSTRALIA & NEW ZEALAND
      • 9.3.5.9. REST OF ASIA-PACIFIC
  • 9.4. REST OF WORLD
    • 9.4.1. MARKET SIZE & ESTIMATES
    • 9.4.2. KEY GROWTH ENABLERS
    • 9.4.3. KEY CHALLENGES
    • 9.4.4. KEY PLAYERS
    • 9.4.5. REGIONAL ANALYSIS
      • 9.4.5.1. LATIN AMERICA
      • 9.4.5.2. MIDDLE EAST & AFRICA

10. COMPETITIVE LANDSCAPE

  • 10.1. KEY STRATEGIC DEVELOPMENTS
    • 10.1.1. MERGERS & ACQUISITIONS
    • 10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 10.1.3. PARTNERSHIPS & AGREEMENTS
    • 10.1.4. BUSINESS EXPANSIONS & DIVESTITURES
  • 10.2. COMPANY PROFILES
    • 10.2.1. AGILENT TECHNOLOGIES INC
    • 10.2.2. ASTRAZENECA PLC
    • 10.2.3. BAYER AG
    • 10.2.4. CHARLES RIVER LABORATORIES INTERNATIONAL INC
    • 10.2.5. ELI LILLY AND COMPANY
    • 10.2.6. EVOTEC SE
    • 10.2.7. GLAXOSMITHKLINE PLC
    • 10.2.8. ICON PLC
    • 10.2.9. IQVIA HOLDINGS INC
    • 10.2.10. JOHNSON & JOHNSON
    • 10.2.11. MERCK & CO INC
    • 10.2.12. NOVARTIS AG
    • 10.2.13. PFIZER INC
    • 10.2.14. ROCHE AG